Tickers

1. Composite Trajectory Verdict

All three statements carry roughly equal weight for CNK given its capital-intensive exhibition model with high fixed lease costs, significant debt service obligations, and an active shareholder return program that directly draws on cash and equity.

Composite Trajectory: Mixed

Revenue grew 2.1% year-over-year to $3.115B in 2025 (10-K 2025-12-31, MD&A), but operating income fell 7.3% to $333.2M and operating margin compressed to 10.7% from 11.8% in 2024 (10-K 2025-12-31, MD&A). Operating cash flow declined 15% to $396.1M while free cash flow (operating less investing) dropped roughly 41% to $186.9M (10-K 2025-12-31, MD&A). The balance sheet shows reduced long-term debt ($1.897B vs $2.364B) and a compliant leverage ratio of 2.51x (10-K 2025-12-31, MD&A), yet cash fell 63% to $688M and total equity fell 45% to $1.325B due to $275M in share repurchases, $40M in dividends, and $196M in warrant settlement cash (10-K 2025-12-31, MD&A; 10-K 2025-12-31, Balance Sheet).

2. Red Flags

• Operating margin compressed to 10.7% in 2025 from 11.8% in 2024 despite 2.1% revenue growth, as total cost of operations rose to 89.3% of revenue from 88.2% (10-K 2025-12-31, MD&A).
• Operating cash flow fell 15% YoY to $396.1M while revenue grew 2.1%, driven by "timing of payments to vendors" (10-K 2025-12-31, MD&A).
• Free cash flow (operating less investing) dropped ~41% YoY to ~$187M from ~$319M as capex jumped to $218.9M from $150.8M (10-K 2025-12-31, MD&A).
• Cash and cash equivalents plunged 63% to $688M from $1.885B, largely funding $460M convertible note repayment, $196M warrant settlement cash, $275M share repurchases, and $40M dividends (10-K 2025-12-31, MD&A; 10-K 2025-12-31, Balance Sheet).
• Total equity fell 45% to $1.325B from $2.403B, reflecting the above capital returns and a $39.3M warrant loss (10-K 2025-12-31, MD&A; 10-K 2025-12-31, Balance Sheet).
• NCMI investment swung to a $12.1M mark-to-market loss in 2025 from an $11.0M gain in 2024 (10-K 2025-12-31, MD&A).
• Impairment charges rose to $6.5M (17 theaters) in 2025 from $1.5M (1 theater) in 2024 (10-K 2025-12-31, MD&A).
• G&A expense rose to 7.6% of revenue in 2025 from 6.5% in 2023, outpacing revenue growth (10-K 2025-12-31, MD&A).
• Concession supplies cost rate increased to 19.6% of concession revenue in 2025 from 18.6% in 2023 (10-K 2025-12-31, MD&A).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Deteriorating

Overall Assessment -- Operating income declined for the second consecutive year, falling to $333.2M in 2025 from $359.3M in 2024 and $362.9M in 2023 (10-K 2025-12-31, MD&A). Operating margin compressed 110 basis points to 10.7% as cost-of-operations ratio rose to 89.3% from 88.2% (10-K 2025-12-31, MD&A). Film rental rate increased to 56.8% of admissions revenue from 56.5%, concession supplies rate rose to 19.6% from 18.8%, and G&A rose to 7.6% of total revenue from 7.2% (10-K 2025-12-31, MD&A). Attendance fell 4.0% consolidated (U.S. -2.1%, International -7.0%), offset by average ticket price (+5.7%) and concession per patron (+6.7%) gains (10-K 2025-12-31, MD&A). Below operating income, a $39.3M warrant loss, $12.1M NCMI mark-to-market loss, and $9.8M foreign currency loss further pressured pre-tax earnings (10-K 2025-12-31, MD&A).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Overall Assessment -- Cash provided by operating activities fell 15% to $396.1M in 2025 from $466.0M in 2024 (10-K 2025-12-31, MD&A). Cash used in investing activities increased 42% to $209.2M from $146.9M, driven by capex rising to $218.9M from $150.8M (10-K 2025-12-31, MD&A). Free cash flow (operating less investing) therefore dropped approximately 41% to ~$187M. Cash used in financing activities surged to $913.1M from $103.1M, reflecting $460M convertible note principal repayment, ~$196M warrant settlement cash, $275M share repurchases, and $40M dividends (10-K 2025-12-31, MD&A). The net result was a $688M year-end cash balance, down 63% from $1.885B (10-K 2025-12-31, Balance Sheet).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Overall Assessment -- Long-term debt carrying value decreased 20% to $1.897B from $2.364B, primarily due to the $460M maturity of the 4.50% Convertible Senior Notes (10-K 2025-12-31, MD&A; 10-K 2025-12-31, Balance Sheet). The Consolidated Net Total Leverage Ratio improved to 2.51x, well within the 2.75x restricted payment threshold (10-K 2025-12-31, MD&A). However, cash fell 63% to $688M, total assets declined 11% to $8.906B, and total equity fell 45% to $1.325B due to share repurchases ($275M), dividends ($40M), warrant settlement ($196M cash + $98M stock), and the $39.3M warrant loss (10-K 2025-12-31, MD&A; 10-K 2025-12-31, Balance Sheet). Current portion of long-term debt dropped to $12.8M from $470.7M with the convertible notes extinguished (10-K 2025-12-31, Balance Sheet). Operating lease obligations remained substantial at ~$1.006B total (10-K 2025-12-31, MD&A).

6. Data Gaps

• Quarterly income statement, cash flow, and balance sheet data from the four 10-Q filings (2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2) — not present in the provided section.
• Full consolidated statements of operations (net income, EPS) for 2023–2025 — XBRL data truncated in the provided 10-K.
• Detailed cash flow statement line items (changes in working capital, non-cash charges) for 2023–2025 — only summary figures in MD&A.
• Segment-level quarterly trends (U.S. vs International revenue, attendance, per-patron metrics) for YoY quarterly comparisons.
• Comparable prior-year quarters for 2026-Q1 and 2026-Q2 to compute YoY quarterly growth rates.